Ignite Creation Date:
2024-05-06 @ 2:51 PM
Last Modification Date:
2024-10-26 @ 1:38 PM
Study NCT ID:
NCT04442022
Status:
RECRUITING
Last Update Posted:
2024-06-05
First Post:
2020-06-10
Brief Title:
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum R-GDP with or Without Selinexor in Patients with RelapsedRefractory Diffuse Large B-cell Lymphoma
Sponsor:
Karyopharm Therapeutics Inc
Organization:
Karyopharm Therapeutics Inc
Organization Data
Organization:
Karyopharm Therapeutics Inc
Class:
INDUSTRY
Study ID:
XPORT-DLBCL-030
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Karyopharm Therapeutics Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None